Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship

被引：1
|
作者：
Rubboli, Andrea [1 ]
Verheugt, Freek W. A. [2 ]
机构：
[1] Osped Maggiore Bologna, Lab Intervent Cardiol, Div Cardiol, Largo Nigrisoli 2, I-40133 Bologna, Italy
[2] OLVG, Heartctr, Dept Cardiol, Oosterpk 9, NL-1091 AC Amsterdam, Netherlands
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2016年 / 223卷
关键词：
Non-vitamin K-antagonist oral anticoagulants; Oral anticoagulation; ATRIAL-FIBRILLATION; RENAL-FUNCTION; WARFARIN; RIVAROXABAN; DABIGATRAN; APIXABAN; EFFICACY; SAFETY;
D O I：
10.1016/j.ijcard.2016.08.207
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：519 / 520
页数：2
相关论文
共 50 条
  • [21] The Use of Non-Vitamin K Antagonist Oral Anticoagulants in Post-Kidney Transplantation, Single-Center Experience
    Zaitoun, Mohammad F.
    El Sheikh, Mahmoud
    Al Faifi, Abdullah S.
    Mahedy, Ahmed W.
    El Nazer, Weam
    El Hennawy, Hany M.
    TRANSPLANTATION PROCEEDINGS, 2021, 53 (10) : 2918 - 2922
  • [22] Non-vitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation: safety issues in the elderly
    Ajam, Tarek
    Cumpian, Tabitha L.
    Tilkens, Blair L.
    Jahangir, Imaan A.
    Frost, Jared
    Ceretto, Cheryl
    Jahangir, Arshad
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2020, 13 (12) : 1309 - 1327
  • [23] How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?
    De Caterina, Raffaele
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0I) : 1 - 6
  • [24] Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory
    Blann, A. D.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2014, 71 (04) : 158 - 167
  • [25] Electrophysiological effects of non-vitamin K antagonist oral anticoagulants on atrial repolarizing potassium channels
    Wiedmann, Felix
    Schlund, Daniel
    Kraft, Manuel
    Nietfeld, Jendrik
    Katus, Hugo A.
    Schmidt, Constanze
    Thomas, Dierk
    EUROPACE, 2020, 22 (09): : 1409 - 1418
  • [26] Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients
    Zhu, Wengen
    Ye, Zi
    Chen, Shilan
    Wu, Dexi
    He, Jiangui
    Dong, Yugang
    Lip, Gregory Y. H.
    Liu, Chen
    STROKE, 2021, 52 (04) : 1225 - 1233
  • [27] Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations
    Saraf, Karan
    Morris, Paul
    Garg, Pankaj
    Sheridan, Paul
    Storey, Robert
    POSTGRADUATE MEDICAL JOURNAL, 2014, 90 (1067) : 520 - 528
  • [28] Safety of non-vitamin K antagonist oral anticoagulants - coronary risks
    Caldeira, Daniel
    Ferreira, Joaquim J.
    Pinto, Fausto J.
    Costa, Joao
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 731 - 740
  • [29] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [30] Newer non-vitamin K-antagonist direct oral anticoagulants in acute coronary syndromes
    Rubboli, Andrea
    ITALIAN JOURNAL OF MEDICINE, 2013, 7 : 22 - 28
12345